Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1

Cell Host & Microbe(2024)10.1016/j.chom.2024.01.014Source: DataRank Database

XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1 is a research paper published in Cell Host & Microbe (2024). On theSindex it has a DataRank of 7.6. It has been cited 179 times, with 169 citing works in its 1-hop citation network.

N/A

7.6DataRank · unranked

Scored on demand from live citation data

Open Access179 citations · 169 citing works in its network

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 53.67)OA: hybridTopics (40)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 10%Citation Network 90%

Base Score Contribution

0.779

From this paper's citation signal

Citation Network Contribution

6.8

From 132 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 169 citers.

Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024
MMWR Morbidity and Mortality Weekly Report202478 citations12 referencesContributes 0.364
Evaluating Humoral Immunity Elicited by XBB.1.5 Monovalent COVID-19 Vaccine
Emerging infectious diseases20247 citations6 referencesContributes 0.347
Effectiveness of BNT162b2 XBB Vaccine Against XBB and JN.1 Sublineages
Open Forum Infectious Diseases202428 citations10 referencesContributes 0.337
Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster
International Journal of Infectious Diseases202426 citations14 referencesContributes 0.235
Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023–January 2024
Vaccine202424 citations16 referencesContributes 0.201

Authors (9)

Yicheng Guo ORCID,Anthony Bowen ORCID,Ian A. Mellis ORCID,Riccardo Valdez,Carmen Gherasim ORCID

Live enrichment

PubMed:38377995 OpenAlex:https://openalex.org/W4391934251

Bill & Melinda Gates Foundation

Grant: INV019355

National Institutes of Health

Grant: 0258-A709-4609

National Institutes of Health

Grant: 75N93021C00014

National Institutes of Health

Grant: 75N93019C00051

FWCI

53.67

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

hybridLicense: cc-by

journalhttps://doi.org/10.1016/j.chom.2024.01.014

publisherhttps://doi.org/10.1016/j.chom.2024.01.014

publisherhttps://api.elsevier.com/content/article/PII:S1931312824000180?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1931312824000180?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38377995

Fields of Study

SARS-CoV-2 and COVID-19 ResearchViral gastroenteritis research and epidemiologyAnimal Virus Infections StudiesHumansmRNA VaccinesAntibodies, NeutralizingCOVID-19 VaccinesAntibodies, Viral

MeSH Terms

COVID-19 VaccinesmRNA VaccinesAntibodies, ViralHumansAntibodies, Neutralizing

Keywords

ImmunogenicityNeutralizing antibodyBiologyVirologyTiterAntibodyMessenger RNASpike ProteinBooster (rocketry)Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirusImmunologyGeneMedicineGeneticsInfectious disease (medical specialty)COVID-19HK.3HV.1JD.1.1JN.1Omicron subvariantsSARS-CoV-2XBB.1.5 monovalent mRNA vaccineimmunological imprintingserum neutralization

Sustainable Development Goals

SDG 0: Good health and well-being